The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer

Trial Profile

The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Exemestane (Primary) ; Anastrozole; Celecoxib
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Mar 2016 New trial record
    • 04 Jun 2012 Results from an analysis in women with osteoporosis have been presented at ASCO-2012 according to a Canadian Cancer Society media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top